The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.

MLA

Zhang, Jinrui, et al. “The Deubiquitylase USP2 Maintains ErbB2 Abundance via Counteracting Endocytic Degradation and Represents a Therapeutic Target in ErbB2-Positive Breast Cancer.” Cell Death and Differentiation, vol. 27, no. 9, Sept. 2020, pp. 2710–25. EBSCOhost, https://doi.org/10.1038/s41418-020-0538-8.

APA

Zhang, J., Liu, S., Li, Q., Shi, Y., Wu, Y., Liu, F., Wang, S., Zaky, M. Y., Yousuf, W., Sun, Q., Guo, D., Wang, T., Zhang, Y., Wang, Y., Li, M., & Liu, H. (2020). The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death and Differentiation, 27(9), 2710–2725. https://doi.org/10.1038/s41418-020-0538-8

Chicago

Zhang, Jinrui, Shuyan Liu, Qiong Li, Yulin Shi, Yueguang Wu, Fang Liu, Shanshan Wang, et al. 2020. “The Deubiquitylase USP2 Maintains ErbB2 Abundance via Counteracting Endocytic Degradation and Represents a Therapeutic Target in ErbB2-Positive Breast Cancer.” Cell Death and Differentiation 27 (9): 2710–25. doi:10.1038/s41418-020-0538-8.